Revolution Medicines (NASDAQ:RVMD) Shares Climb 5.3% – Here’s Why

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report)’s stock price traded up 5.3% during trading on Friday. The stock traded as high as $166.31 and last traded at $167.8150. 617,670 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 2,800,772 shares. The stock had previously closed at $159.43.

Trending Headlines about Revolution Medicines

These are some of the RVMD headlines that stood out recently:

Analysts Set New Price Targets

RVMD has been the topic of a number of research analyst reports. Oppenheimer raised their target price on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. Brookline Capital Markets started coverage on shares of Revolution Medicines in a research note on Monday, September 28th. They issued a “buy” rating and a $318.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $275.00 price objective on shares of Revolution Medicines in a research report on Thursday, October 15th. Raymond James Financial reissued a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a research note on Thursday, August 27th. Finally, TD Cowen lifted their price target on shares of Revolution Medicines from $250.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of “Moderate Buy” and an average target price of $262.75.

Get Our Latest Analysis on RVMD

Revolution Medicines Stock Performance

The company has a quick ratio of 8.34, a current ratio of 8.36 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average price of $190.01 and a 200 day moving average price of $161.04. The stock has a market cap of $34.74 billion, a PE ratio of -17.63 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter in the prior year, the company earned ($1.61) earnings per share. Analysts expect that Revolution Medicines, Inc. will post -7.41 earnings per share for the current year.

Insider Activity

In other news, insider Mark Goldsmith sold 13,988 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $2,786,969.12. Following the transaction, the insider owned 253,342 shares in the company, valued at approximately $50,475,860.08. This trade represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elizabeth Anderson sold 10,143 shares of Revolution Medicines stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the transaction, the director directly owned 4,333 shares in the company, valued at approximately $836,442.32. The trade was a 70.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 273,901 shares of company stock valued at $53,970,418. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

Several large investors have recently bought and sold shares of RVMD. American Century Companies Inc. grew its stake in Revolution Medicines by 9,765.6% in the third quarter. American Century Companies Inc. now owns 503,835 shares of the company’s stock worth $103,417,000 after purchasing an additional 498,728 shares during the period. Militia Capital Management LLC lifted its position in Revolution Medicines by 0.9% during the third quarter. Militia Capital Management LLC now owns 20,170 shares of the company’s stock valued at $4,140,000 after buying an additional 170 shares during the period. Defiance ETFs LLC bought a new stake in shares of Revolution Medicines during the 3rd quarter valued at $237,000. Kestra Advisory Services LLC boosted its holdings in shares of Revolution Medicines by 236.7% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,306 shares of the company’s stock valued at $884,000 after buying an additional 3,027 shares in the last quarter. Finally, Coastal Bridge Advisors LLC purchased a new stake in shares of Revolution Medicines in the 3rd quarter worth about $361,000. 94.34% of the stock is owned by institutional investors.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Further Reading

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.